Immunology — Revenue
Eli Lilly Immunology — Revenue decreased by 21.9% to $1.20B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 10.6%, from $1.09B to $1.20B. Over 4 years (FY 2021 to FY 2025), Immunology — Revenue shows an upward trend with a 11.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates successful market penetration, strong demand for existing therapies, or the successful launch of new immunology products, while a decrease may signal increased competition, patent expirations, or loss of market share.
Detailed definition
This metric represents the total net sales generated from the company's portfolio of immunology-focused pharmaceutical p...
Peer comparison
Comparable to immunology or specialty medicine segment revenues reported by major pharmaceutical peers, often benchmarked against therapeutic area growth rates.
lly_segment_immunology_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $785.40M | $1.00B | $956.60M | $748.10M | $796.50M | $866.40M | $933.60M | $777.80M | $928.50M | $986.90M | $1.10B | $834.00M | $1.08B | $1.19B | $1.29B | $1.09B | $1.26B | $1.36B | $1.54B | $1.20B |
| QoQ Change | — | +27.9% | -4.8% | -21.8% | +6.5% | +8.8% | +7.8% | -16.7% | +19.4% | +6.3% | +11.9% | -24.5% | +29.8% | +9.5% | +8.9% | -15.7% | +15.4% | +8.5% | +13.1% | -21.9% |
| YoY Change | — | — | — | — | +1.4% | -13.8% | -2.4% | +4.0% | +16.6% | +13.9% | +18.3% | +7.2% | +16.6% | +20.1% | +16.9% | +30.5% | +16.0% | +14.9% | +19.4% | +10.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's immunology — revenue?
- Eli Lilly (LLY) reported immunology — revenue of $1.20B in Q1 2026.
- How has Eli Lilly's immunology — revenue changed year-over-year?
- Eli Lilly's immunology — revenue increased by 10.6% year-over-year, from $1.09B to $1.20B.
- What is the long-term trend for Eli Lilly's immunology — revenue?
- Over 4 years (2021 to 2025), Eli Lilly's immunology — revenue has grown at a 11.8% compound annual growth rate (CAGR), from $3.36B to $5.25B.
- What does immunology — revenue mean?
- The total revenue earned from the sale of immunology-related pharmaceutical products.